COMPANY NEWS


Natco Pharma Ltd
BSE Code 524816 ISIN Demat INE987B01026 Book Value (₹) 284.47 NSE Symbol NATCOPHARM Div & Yield % 0.55 Market Cap ( Cr.) 18,248.61 P/E * 15.06 EPS * 67.65 Face Value (₹) 2
* Profit to Earning Ratio
* Earning Per Share
Natco Pharma update on litigation regarding Pomalidomide capsules Back
(21 Dec 2023)
Natco Pharma announced that Celgene Corporation, Bristol Myers Squibb Company, Breckenridge Pharmaceutical Inc. and Natco Pharma have been named defendants in an antitrust lawsuit in the US by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Louisiana and HMO Louisiana, Inc., regarding Pomalidomide (POMALYST) capsules.

The plaintiffs voluntarily dismissed Breckenridge Pharmaceutical Inc. and Natco Pharma from the case. All claims against the Company in the litigation have now been dismissed.

Breckenridge is the ANDA holder and front-end marketing partner for the Pomalidomide capsules generic product in the US.

Natco's Pomalidomide capsules generic product has not yet launched in the US.